NkMax Co., Ltd. logo

NkMax Co., Ltd. (182400)

Market Closed
25 Mar, 06:30
KRX SM KRX SM
2,020. 00
0
0%
172.74B Market Cap
- P/E Ratio
0% Div Yield
0 Volume
- Eps
2,020
Previous Close
Day Range
2,020 2,020
Year Range
1,550 8,205
Want to track 182400 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

182400 closed Monday higher at ₩2,020, an increase of 0% from Friday's close, completing a monthly increase of 0% or ₩2,020. Over the past 12 months, 182400 stock gained 0%.
182400 is not paying dividends to its shareholders.
The last earnings report, released on Nov 12, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
NkMax Co., Ltd. has completed 2 stock splits, with the recent split occurring on Jun 24, 2025.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on KRX SM (KRW).

182400 Chart

Similar

Macrogen Inc.
16,930
+0.36%
YG-1 Co., Ltd.
5,530
0%
Vieworks Co., Ltd.
20,350
-0.73%
GeneOne Life Science Inc.
2,070
-0.24%
Iljin Diamond Co. Ltd.
12,630
+1.04%

NkMax Co., Ltd. (182400) FAQ

What is the stock price today?

The current price is ₩2,020.00.

On which exchange is it traded?

NkMax Co., Ltd. is listed on KRX SM.

What is its stock symbol?

The ticker symbol is 182400.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 172.74B.

Has NkMax Co., Ltd. ever had a stock split?

NkMax Co., Ltd. had 2 splits and the recent split was on Jun 24, 2025.

NkMax Co., Ltd. Profile

Biotechnology Industry
Healthcare Sector
Mr. Sangwoo Park CEO
KRX SM Exchange
- ISIN
South Korea Country
134 Employees
- Last Dividend
24 Jun 2025 Last Split
- IPO Date

Overview

NKMAX CO., Ltd. is a South Korean biotechnology firm that specializes in the development, manufacture, and sale of biological products. Founded in 2002 and headquartered in Seongnam-si, South Korea, NKMAX has emerged as a leader in immunotherapy treatments, particularly for cancer. The company initially operated under the name ATGen Co before rebranding to NKMAX CO., Ltd. in 2019. Its focus is on leveraging the power of the immune system to combat cancer, enhancing the body’s natural killer (NK) cells' ability to destroy cancer cells. NKMAX’s innovative approach to cancer treatment and immune system support has positioned it at the forefront of the biotechnology sector in South Korea.

Products and Services

  • Anti-cancer Immunotherapy Treatment
  • This cutting-edge treatment is designed to activate the immune cells within the body to target and kill cancer cells. Utilizing the body's own defense mechanisms, this therapy offers a promising avenue for cancer treatment.

  • Natural Killer Cell Activity Test for Cancer Patients
  • A diagnostic service that evaluates the activity of natural killer cells in cancer patients. By analyzing the body's natural defense against cancer, this test helps in understanding the patient's immune response to cancer.

  • NK VUE Kit
  • The NK VUE Kit is an innovative test kit that measures the activity of NK cells by quantitatively assessing the level of IFN-gamma released from activated NK cells with just a small amount of blood. This allows for an efficient and effective evaluation of the immune system's capacity to combat cancer.

  • NK365
  • A proprietary blend of vitamins, minerals, and Agaricus mushroom extract, NK365 is designed to support and enhance the immune system. This dietary supplement provides nutritional support aimed at maintaining optimal immune function.

  • Recombinant Proteins and Monoclonal Antibodies
  • NKMAX CO., Ltd. also specializes in the production of recombinant proteins and monoclonal antibodies, which are critical components in the development of various therapeutic and diagnostic applications in the realm of biomedicine.

  • NK PUPPY
  • Extending its innovative approach to animal health, NKMAX has developed NK PUPPY, a test that measures a dog's immunity. This test provides pet owners and veterinarians with crucial information on the immune status of dogs, aiding in the management of their health and well-being.

Contact Information

Address: 172, Dolma-ro
Phone: 82 31 8017 8114